Top Story

Apellis to acquire Potentia Pharmaceuticals

November 21, 2014

Apellis Pharmaceuticals has entered into an agreement to acquire Potentia Pharmaceuticals, according to a press release.

Through the agreement, Apellis obtained the necessary intellectual property rights to develop a complement inhibitor drug compound (APL-2) for the treatment of dry age-related macular degeneration.

Imprimis reports $2.5 million net loss in third quarter

November 21, 2014
Imprimis Pharmaceuticals reported a net loss of $2.5 million, or $0.27 per common share, in the third quarter, compared with a loss of $2.1 million, or $0.23 per common…

Ocular Therapeutix to evaluate sustained-release travoprost for glaucoma, ocular hypertension

November 21, 2014
Ocular Therapeutix has begun enrolling the first subjects in a phase 2b clinical trial to evaluate the safety and efficacy of sustained-release travoprost, according to…

Valeant announces $2 billion Securities Repurchase Program

November 20, 2014
A new securities repurchase program that will allow Valeant Pharmaceuticals to make purchases up to $2 billion of its senior notes, common shares and other securities…
CME
Postoperative Inflammation and Pain

Postoperative Inflammation and Pain: Elimination of the Dynamic Duo to Improve Patient Outcomes

This activity is supported by an educational grant from Bausch + Lomb.

Cataract surgery has improved in both safety and outcomes in recent years. With advances in surgical techniques…
More »
Video
John Hovanesian th

Omeros granted CMS pass-through reimbursement status for Omidria

October 31, 2014
The Center for Medicare and Medicaid Services has granted Omeros Corporation with transitional pass-through status for…
More »

Apellis to acquire Potentia Pharmaceuticals

November 21, 2014
Apellis Pharmaceuticals has entered into an agreement to acquire Potentia Pharmaceuticals, according to a press release.Through the agreement…

Imprimis reports $2.5 million net loss in third quarter

November 21, 2014
Imprimis Pharmaceuticals reported a net loss of $2.5 million, or $0.27 per common share, in the third quarter, compared with a loss of $2.1 million…

Ocular Therapeutix to evaluate sustained-release travoprost for glaucoma, ocular hypertension

November 21, 2014
Ocular Therapeutix has begun enrolling the first subjects in a phase 2b clinical trial to evaluate the safety and efficacy of sustained-release…

Valeant announces $2 billion Securities Repurchase Program

November 20, 2014
A new securities repurchase program that will allow Valeant Pharmaceuticals to make purchases up to $2 billion of its senior notes, common shares and…

Optos reports 7% increase in third-quarter revenue

November 20, 2014
Optos totaled $170.6 million in revenue and operating income in the third quarter, a 7% increase from $159.5 million in the third quarter 2013…

5 things to read during Contact Lens Health Week

November 19, 2014
The U.S. Centers for Disease Control and Prevention and the American Optometric Association have partnered to launch Contact Lens Health Week, an…

Ophthotec reports $39.6 million revenue in third quarter

November 19, 2014
Ophthotec reported $39.6 million in revenue in the third quarter, as well as a 9-month net loss of $62.3 million, according to a company press…
Meeting News Coverage

CooperVision launches daily disposable silicone hydrogels

November 19, 2014
DENVER – CooperVision introduced Clariti 1 Day, its family of silicone hydrogel daily disposable lenses, here at the American Academy of…
Meeting News Coverage

Heidelberg upgrades Spectralis glaucoma module

November 18, 2014
DENVER – The Glaucoma Module Premium Edition for Heidelberg Engineering’s Spectralis is pending 510 clearance from the U.S. Food and Drug…
Meeting News Coverage

Oculus presents Keratograph 5M for dry eye diagnostics

November 17, 2014
DENVER – Oculus introduced the Keratograph 5M, a high-resolution color camera, for use in diagnosing dry eye syndrome, here at the American…
More Headlines »
morganatic-roan
morganatic-roan